key: cord-0936012-v6eukyuo authors: Patel, H.; Ashton, N. J.; Dobson, R. J.; Anderson, L.-m.; Yilmaz, A.; Blennow, K.; Gisslen, M.; Zetterberg, H. title: Proteomic blood profiling in mild, severe and critical COVID-19 patients date: 2020-06-23 journal: nan DOI: 10.1101/2020.06.22.20137216 sha: fd96decb87ab3982be89068ce699a2676a1c3c74 doc_id: 936012 cord_uid: v6eukyuo The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in the majority of individuals leading to COVID-19 disease. However, in some infected individuals, this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to multi-organ failure and death. The purpose of this study is to explore the proteomic differences between mild, severe and critical COVID-19 positive patients. Blood protein profiling was performed on 59 COVID-19 mild (n=26), severe (n=9) or critical (n=24) cases and 28 controls using the OLINK inflammation, autoimmune, cardiovascular and neurology panels. Differential expression analysis was performed within and between disease groups to generate nine different analyses. From the 368 proteins measured per individual, more than 75% were observed to be significantly perturbed in COVID-19 cases. Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were identified to be associated with disease severity. The results have been made readily available through an interactive web-based application for instant data exploration and visualization, and can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/. Our results demonstrate that dynamic changes in blood proteins that associate with disease severity can potentially be used as early biomarkers to monitor disease severity in COVID-19 and serve as potential therapeutic targets. . The complete differential expression (DE) results for all analyses are available in 144 Supplementary Table 2 and can also be explored using the data explorer application developed 145 in this study (https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/). 146 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The most significantly enriched pathway was the "Cytokine-cytokine receptor interaction" (FDR adjusted p-value = 1.72 e-41). The pathway, along with the enriched proteins, is 170 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. was generated using the "KEGG mapper -Search&Color Pathway" (Kanehisa & Sato, 2020) . Proteins associated with COVID-19 severity 180 Eleven proteins were identified to be significantly differentially expressed between the control, 181 the mild, the severe and the critical symptom groups. Eight of these proteins were consistently 182 perturbed in the same direction as the infection symptoms increased (control -> mild -> severe 183 -> critical). Due to the presence of the duplicate proteins across the different panels, these eight 184 proteins correspond to six unique proteins. The six proteins are IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1, and are deemed to be associated with COVID-19 severity. None of these 186 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. The IL6 protein was discovered to have been repeated on three different panels, and its 189 expression pattern and significance level were found to be very similar between the disease The expression of all six proteins was observed to significantly increase from the control group 197 to the mild group, which then further increases in the severe group, and increases even further 198 in the critical group. Their expression patterns for these proteins is shown in Figure 3 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. to be significantly perturbed in both the "mild group longitudinal" and the "critical group 222 longitudinal" analyses. 223 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. 228 The three proteins measured on the Simoa platform were absent from the OLINK platform. The three proteins tau, NfL and GFAP were significantly (p-value ≤ 0.05) correlated with 97, NfL was identified to be most correlated with EDA2R (r=0.66, p-value=4.01e-12), which is 233 not significantly perturbed in any of the nine DE analysis performed in this study (see Figure 234 4a). Tau and GFAP were identified to be both most correlated with SCARB2 (tau: r=0.39 and 235 p-value=1.74e-4, GFAP: r=0.46, p-value=6.47e-6). When compared to controls, SCARB2 is 236 significantly up-regulated in the mild (logFC=0.59, p-value=4.7e-3) and critical groups 237 (logFC=0.72, p-value=0.01) but not in the severe group (logFC=1.02, p-value=0.12). Although 238 SCRAB2 is not statistically associated with disease severity, the expression of this protein is 239 noted to increase inline with disease severity (Figure 4b) . 240 In addition, biomarkers of disease severity ( Figure 3) were vastly more associated with NfL 241 (CKAP4, r=0.642; PD-L1, r=0-623; IL6, r=0.528; Gal-9, LILRB4, r=0.508; r=0.486; IL-1ra, 242 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.22.20137216 doi: medRxiv preprint had blood drawn at two different time points after the onset of disease symptoms. In total nine 271 DE analysis were performed ("control vs mild", "control vs severe", "control vs critical", "mild 272 vs severe", "mild vs critical", "severe vs critical", "control vs case", "mild group longitudinal" (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.22.20137216 doi: medRxiv preprint Biomarkers for infection severity 297 Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were consistently differentially 298 expressed between the control, mild, severe and critical symptom groups. The expression of all 299 six proteins increased as the severity of the symptoms increased, suggesting these proteins may 300 be a useful tool in monitoring the progression from mild to critical disease. Furthermore, these 301 six proteins are not significantly perturbed within the longitudinal analysis, suggesting these 302 proteins are not associated with the length of the duration of infection. Interleukin 6 (IL6) is an inflammatory cytokine that is an endogenous pyrogen of inducing 304 fever in patients with autoimmune diseases or infections. IL6 is an acute phase inflammatory 305 cytokine that has been suggested to reflect the inflammatory state of the lungs. Elevated IL6 306 levels have been discovered in ARDS and lung transplantation complications (4,12), and has 307 already been shown to be elevated in COVID-19 patients (12-14) . Furthermore, it has also 308 been suggested to be associated with increased COVID-19 mortality (15) . Our results add 309 strong support that IL-6 expression increases with disease severity. Furthermore, while not assessed in this study, IL6 does show some evidence of decreasing in 311 disease remission in COVID-19 patients (12,16) and is, therefore, a viable target for treating 312 the cytokine storm during disease progression. Tocilizumab is a monoclonal antibody targeted 313 against IL6 and its receptor (IL6R) inhibitor that is commonly used to treat inflammatory and 314 autoimmune conditions (17). It is currently being investigated in its effectiveness to treat 315 COVID-19 patients (18,19) . 316 In addition to IL6, we have highlighted novel protein markers associated with disease severity 317 in COVID-19 patients and are all involved in the immune system, with many mediating 318 cytokine productions, including IL6. Cytoskeleton Associated Protein 4 (CKAP4) is involved 319 in the innate immune system and mediates the anchoring of endoplasmic reticulum to 320 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. were significantly higher than those of healthy controls, suggesting CKAP4 as a potential early 322 biomarker for lung cancer (21) . Galectin 9 (Gal-9) belongs to a family of beta-galactoside- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. Due to blood samples being taken as part of a routine hospital procedure during an 408 unprecedented time, this study was restricted to a small cohort, certain aspects of this study 409 design were uncontrollable and valuable information was unobtainable. The number of "days 410 since symptom onset", was identified to be significantly higher in the mild symptom group 411 when compared to the severe and the critical symptom group. Essentially, following the onset 412 of symptoms, samples were drawn from the mild symptom group at a much later date when 413 compared to the severe and the critical symptom group. As a result, expression changes 414 involving the mild group ("mild vs severe" and "mild vs critical") may reflect the duration a 415 patient has been infected with COVID-19 rather than being a reflection of symptom severity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. This extensive proteomic analysis unbiasedly identified IL6 and five novel proteins (CKAP4, 429 Gal-9, IL-1ra, LILRB4 and PD-L1) to be associated with disease severity in COVID-19 cases. Elevated levels of proteins significantly increased as the disease symptom severity deteriorated 431 and highlight a shared mechanism of cytokine-mediated lung injury cause by viral injection. These proteins warrant further investigation but could provide potential as early biomarkers for 433 disease severity and may serve as potential therapeutic targets, or as biomarkers to monitor the 434 effect of treatments to modulate the immune system and/or suppress the infection. Overall, the 435 results of this study further increase the understanding of COVID-19, which includes CNS 436 involvement, and have been made widely available to researchers as an interactive web-based 437 tool accessible at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The proteomic data is available in the BioStudies database (http://www.ebi.ac.uk/biostudies) 513 under accession number S-BSST416. Additionally, an R shiny application was written in R 514 using the "shiny" framework (version 1.4.0.2) to allow the quick and efficient visualization of 515 the expression of specific proteins across the control, mild, severe and severe symptom groups. The application is hosted on the research computing facility at King's College London (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 23, 2020. . https://doi.org/10.1101/2020.06.22.20137216 doi: medRxiv preprint World Health Organization Clinical characteristics of Neurochemical evidence of astrocytic and neuronal injury commonly found in 598 COVID-19 The wizard requires protein stability to function as a 602 tumor suppressor Nonsteroidal sulfamate derivatives as new therapeutic approaches for 606 Neurofibromatosis 2 (NF2) Molecular insights into NF2/Merlin tumor suppressor 608 function The role of interleukin-6 in 610 monitoring severe case of coronavirus disease 2019 Epidemiological and clinical 614 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 615 descriptive study Clinical predictors of mortality due to 617 COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive 618 Care Medicine Elevated Interleukin-6 and Severe COVID-19: A Meta-620 Responsive Encephalitis in Coronavirus Disease DrugBank: a comprehensive resource for in silico drug discovery and 627 exploration First case of COVID-19 in a 629 patient with multiple myeloma successfully treated with tocilizumab Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory 633 failure: a case report UniProt: A worldwide hub of protein knowledge Cytoskeleton-Associated Protein 4 Is a Novel Serodiagnostic Marker for Lung Cancer Induces Maturation of Human Monocyte-Derived Dendritic Cells Elevated cerebrospinal fluid Galectin-9 is associated with central nervous 649 system immune activation and poor cognitive performance in older HIV-infected 650 individuals A 652 crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in 653 hepatitis C infection Plasma levels of Galectin-9 reflect disease severity in malaria infection Exuberant elevation of IP-10 MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity 659 and fatal outcome. medRxiv Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe 663 Coronavirus disease 2019: A case report Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute 668 respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Leukocyte Ig-like 672 receptor B4 (LILRB4) is a potent inhibitor of FcγRI-mediated monocyte activation via 673 dephosphorylation of multiple kinases The evolving landscape of biomarkers for checkpoint 675 inhibitor immunotherapy Do checkpoint inhibitors compromise the cancer patients' 678 immunity and increase the vulnerability to COVID-19 infection? Immunotherapy Mesencephalic 681 astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes 682 behavioral recovery in rats Sars-Cov-2: Underestimated damage to nervous 685 system. Travel Medicine and Infectious Disease et 687 al. Presenting Characteristics, Comorbidities, and Outcomes Among Hospitalized With COVID-19 in the New York City Area Detection 692 of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, 696 and Excellent Scalability ConsensusPathDB -A database for 700 integrating human functional interaction networks KEGG Mapper for inferring cellular functions from protein 703 sequences